01 1Cipla
01 1GEFITINIB
01 1India
01 1Active
01 1Complete
GDUFA
DMF Review : Complete
Rev. Date : 2017-10-27
Pay. Date : 2017-09-13
DMF Number : 29090
Submission : 2015-03-23
Status : Active
Type : II
20
Cipla Ltd, based in India, is a pharmaceutical company that stands out with its certifications from FDA, EDQM and WHO-GMP.
One of their notable products is GEFITINIB, with a corresponding US DMF Number 29090.
Remarkably, this DMF maintains an Active status since its submission on March 23, 2015, highlighting commitment to regulatory compliance.
Their GDUFA DMF Review was successfully complete, with a review date of October 27, 2017, and payment made on September 13, 2017, indicating their dedication to facilitating drug approvals, Categorized as Type II
